

March 30, 2022



CytoDyn to Hold Webcast to Provide Company Update

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --**CytoDyn Inc. (OTCQB: CYDY)** ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.

Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.

Date: Thursday, March 31, 2022

Time: 5:30 am PT / 8:30 am ET

Access: <https://services.choruscall.com/mediaframe/webcast.html?webcastid=v9IRoWUq>

Questions: Prior to the webcast, questions can be submitted online to ir@cytodyn.com

This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until April 30, 2022.

CONTACTS

Investors:

Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com

Media:

Dan Zacchei / Joe Germani
Sloane & Company
dzacchei@sloanepr.com / jgermani@sloanepr.com